Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 872,928
  • Shares Outstanding, K 69,280
  • Annual Sales, $ 8,010 K
  • Annual Income, $ -110,210 K
  • 36-Month Beta 2.01
  • Price/Sales 109.03
  • Price/Cash Flow N/A
  • Price/Book 3.18

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.40 +11.40%
on 11/30/17
13.55 -6.27%
on 12/11/17
-0.05 (-0.39%)
since 11/15/17
3-Month
11.40 +11.40%
on 11/30/17
20.45 -37.90%
on 10/02/17
-4.50 (-26.16%)
since 09/15/17
52-Week
9.30 +36.56%
on 06/14/17
20.45 -37.90%
on 10/02/17
+1.45 (+12.89%)
since 12/15/16

Most Recent Stories

More News
Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting

Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel G9a program for sickle cell disease (SCD). The data were...

EPZM : 12.70 (+0.79%)
Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company developing novel epigenetic therapies, today announced that two presentations reinforcing its commitment to identifying predictors...

EPZM : 12.70 (+0.79%)
Epizyme to Present at the Jefferies 2017 London Healthcare Conference

Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present a company overview at the Jefferies 2017 London...

EPZM : 12.70 (+0.79%)
Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3

Epizyme (EPZM) posted narrower-than-expected loss in the third quarter of 2017. It plans to meet the FDA to begin the registration strategy for its lead pipeline candidate, tazemetostat, in the next quarter....

AGEN : 3.56 (+1.14%)
LGND : 135.87 (-0.12%)
ADAP : 7.37 (unch)
EPZM : 12.70 (+0.79%)
Epizyme Reports Third Quarter 2017 Operating Results and Company Updates

Company Scheduled for First FDA Interaction for Tazemetostat in NHL in 4Q17

EPZM : 12.70 (+0.79%)
Featured Company News - Epizyme Presented Data from Phase-1 Trial of Tazemetostat In Children with Relapsed/Refractory INI1-Negative Solid Tumors

Research Desk Line-up: Alexion Pharma Post Earnings Coverage

EPZM : 12.70 (+0.79%)
ALXN : 115.76 (+2.36%)
What to Expect From Epizyme (EPZM) This Earnings Season?

Epizyme (EPZM) is a development-stage company, with no approved products in its portfolio. Hence, investor focus is expected to remain on the company's pipeline updates and mainly on its lead candidate,...

EXAS : 51.56 (+0.66%)
CLVS : 64.13 (-0.02%)
RHHBY : 30.9000 (+0.88%)
EPZM : 12.70 (+0.79%)
Epizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced encouraging data from the dose escalation portion of the company's ongoing Phase...

EPZM : 12.70 (+0.79%)
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -

SRRA : 3.14 (-0.63%)
CLVS : 64.13 (-0.02%)
EPZM : 12.70 (+0.79%)
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

- Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -

SRRA : 3.14 (-0.63%)
CLVS : 64.13 (-0.02%)
EPZM : 12.70 (+0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 13.33
1st Resistance Point 13.02
Last Price 12.70
1st Support Level 12.32
2nd Support Level 11.93

See More

52-Week High 20.45
Fibonacci 61.8% 16.19
Fibonacci 50% 14.88
Fibonacci 38.2% 13.56
Last Price 12.70
52-Week Low 9.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.